{
    "nctId": "NCT01815580",
    "officialTitle": "HIV Testing and Treatment to Prevent Onward HIV Transmission Among MSM and Transgender Women in Lima, Peru",
    "inclusionCriteria": "* Adult men who have sex with men, and transgender women\n* Unaware of HIV status at enrollment in follow-up cohort\n* High risk for HIV infection\n* Willing to test for HIV\n* No prior ART, including prior administration of pre- and post-exposure prophylaxis in the last 30 days\n* Willing to provide informed consent\n* Must be MALE\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Prior receipt of investigational anti-HIV vaccine\n* Ongoing therapy with any of the following:\n\n  1. Systemic corticosteroids. Short course less than or equal to 21 days of corticosteroids is allowed\n  2. Systemic chemotherapeutic agents\n  3. Nephrotoxic systemic agents, including aminoglycosides, amphotericin B, cidofovir, cisplatin, foscarnet, pentamidine\n  4. Immunomodulatory treatments including Interleukin-2\n  5. Investigational agents\n* Known allergy/sensitivity or any hypersensitivity to components of study drugs (ART) or their formulations\n* Active drug or alcohol use or dependence that would interfere with adherence to study requirements\n* Serious medical or psychiatric illness that would interfere with the ability to adhere to study requirements\n* Chronic or acute hepatitis B infection\n* Use of female hormonal products based on estrogen or derivatives"
}